BC Week In Review | Nov 16, 2018
Company News

ICER: asthma mAbs should be 50% cheaper for cost effectiveness

The Institute for Clinical and Economic Review (ICER) said the costs of five asthma mAbs would need to decrease by at least 50% to be cost effective in a final evidence report . ICER said that...
BC Week In Review | Sep 28, 2018
Company News

ICER finds asthma mAbs to be not cost-effective

In a draft evidence report , the Institute for Clinical and Economic Review (ICER) found that five biologics approved or in testing to treat asthma were not cost-effective compared with standard of care (SOC) therapies despite...
BC Week In Review | Jun 1, 2018
Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it does not plan to submit regulatory applications for Fasenra benralizumab to treat chronic obstructive pulmonary disease (COPD) after the drug missed the primary endpoint of reducing exacerbations in a...
BC Extra | May 30, 2018
Clinical News

AZ not planning regulatory submissions for Fasenra in COPD

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it does not plan to submit regulatory applications for Fasenra benralizumab to treat chronic obstructive pulmonary disease after the drug missed the primary endpoint of reducing exacerbations in a second...
BC Week In Review | May 18, 2018
Clinical News

AZ's Fasenra fails in Phase III COPD study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab missed the primary endpoint of reducing exacerbations vs. placebo in the Phase III GALATHEA trial to treat chronic obstructive pulmonary disease. The company expects data this quarter from...
BC Extra | May 11, 2018
Clinical News

AZ's Fasenra fails in Phase III COPD study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Fasenra benralizumab missed the primary endpoint of reducing exacerbations vs. placebo in the Phase III GALATHEA trial to treat chronic obstructive pulmonary disease. The company expects data this quarter from...
BC Innovations | Mar 7, 2018
Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Mouse studies suggest inhibiting IL5Rα or CCR3 could help treat intestinal fibrosis caused by abdominal radiation therapy. In a mouse model of abdominal radiation-induced intestinal fibrosis, a mAb targeting IL5Rα, a tool compound...
BioCentury | Apr 8, 2013
Strategy

AstraZeneca's reset

After spending at least $7 billion for late-stage assets in 2012, AstraZeneca plc believes it now has sufficient value in its Phase II/III pipeline to restore long-term growth. The attention of business development is now...
BioCentury | Mar 18, 2013
Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
Items per page:
1 - 9 of 9